5-Amino-1MQ 50mg

5-Amino-1MQ (5-amino-1-methylquinolinium iodide, chemical formula C11H13N2+I−) is a small molecule compound that functions as a highly selective and competitive inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that has emerged as an important regulator of cellular metabolism, energy expenditure, and adiposity. NNMT catalyzes the methylation of nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine.

While this methylation reaction was historically considered a relatively minor metabolic pathway for nicotinamide clearance, research over the past decade has revealed that NNMT plays a surprisingly important and previously underappreciated role in cellular energy metabolism, NAD+ homeostasis, adipocyte biology, and whole metabolic regulation.

While 5-Amino-1MQ research remains in early stages with limited data and no regulatory approvals, the compound has generated substantial interest in metabolic research, biohacking, and composition optimization communities based on the compelling preclinical evidence and novel mechanism of action targeting a previously unexploited metabolic pathway.

5-Amino-1MQ exerts its metabolic effects primarily through competitive inhibition of nicotinamide N-methyltransferase (NNMT), an enzyme belonging to the methyltransferase superfamily that is expressed in multiple tissues including liver, adipose tissue, skeletal muscle, kidney, and brain, with particularly high expression in visceral (abdominal) adipose tissue – the depot most strongly associated with metabolic disease. NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM, the universal methyl donor in cells) to nicotinamide (a form of vitamin B3 and a precursor for NAD+ synthesis), producing 1-methylnicotinamide and S-adenosylhomocysteine (SAH). While this reaction was traditionally viewed as a minor nicotinamide clearance pathway, research has revealed that NNMT activity has far-reaching consequences for cellular metabolism through multiple interconnected mechanisms.

NAD+ Preservation and Sirtuin Activation

First and most directly, NNMT activity consumes nicotinamide, which is a key precursor for NAD+ biosynthesis through the salvage pathway (the predominant NAD+ synthesis route in most mammalian cells). By methylating and removing nicotinamide, NNMT effectively drains NAD+ precursor availability, leading to reduced intracellular NAD+ levels. NAD+ is a critical coenzyme involved in hundreds of enzymatic reactions including glycolysis, the citric acid cycle, and oxidative phosphorylation, as well as serving as a substrate for NAD+-consuming enzymes including sirtuins, PARPs, and CD38.

When 5-Amino-1MQ inhibits NNMT, nicotinamide is preserved and available for NAD+ synthesis, leading to increased intracellular NAD+ concentrations. This NAD+ elevation activates sirtuins, particularly SIRT1 in adipocytes and hepatocytes, which deacetylates and activates numerous metabolic regulatory proteins including PGC-1α, a master regulator of mitochondrial biogenesis, oxidative metabolism, and thermogenesis. SIRT1 activation also promotes fatty acid oxidation, reduces lipogenesis, improves insulin sensitivity, and enhances cellular stress resistance.

Methylation Capacity

Second, NNMT inhibition affects cellular methylation capacity: SAM is required for hundreds of methyltransferase reactions throughout the cell, and NNMT’s consumption of SAM can deplete this critical resource, while the SAH produced by NNMT is a potent product inhibitor of many methyltransferases. By inhibiting NNMT, 5-Amino-1MQ preserves SAM availability and reduces SAH accumulation, potentially supporting proper methylation of DNA, histones, and proteins – epigenetic modifications that regulate gene expression and cellular function.

Browning of White Adipose Tissue

Third, and perhaps most fascinating, NNMT inhibition promotes browning of white adipose tissue – the conversion of white adipocytes into beige/brown adipocytes that contain numerous mitochondria and express uncoupling protein 1 (UCP1), enabling them to dissipate energy as heat through non-shivering thermogenesis. This browning is mediated through multiple pathways including SIRT1/PGC-1α activation, increased expression of thermogenic genes (UCP1, PRDM16, PPARγ), and enhanced mitochondrial biogenesis. Studies show that 5-Amino-1MQ-treated animals have visibly darker (browner) visceral with increased mitochondrial density and oxidative enzyme expression.

Improved Insulin Sensitivity

Fourth, NNMT inhibition improves insulin sensitivity and glucose metabolism through multiple mechanisms including increased NAD+ and SIRT1 activity, reduced adipose tissue inflammation, and improved mitochondrial function. The compound also appears to reduce hepatic steatosis (fatty liver) by enhancing hepatic fatty acid oxidation and reducing lipogenesis. The 1-methylnicotinamide product of NNMT may itself have biological activities (including potential insulin resistance-promoting effects), and reducing its production through NNMT inhibition may contribute to metabolic improvements.

Research on 5-Amino-1MQ is in relatively early stages, with the bulk of published evidence coming from preclinical animal studies, in vitro cell culture experiments, and molecular/biochemical characterization of NNMT’s role in metabolism. Clinical trial data is limited or absent in peer-reviewed literature as of current knowledge, though the compound has gained use in research and biohacking contexts.

Mechanistic Studies

Subsequent research has explored the mechanisms by which NNMT regulates metabolism, with studies demonstrating that NNMT activity reduces cellular NAD+ availability, affects SAM-dependent methylation reactions, modulates sirtuin activity, and influences adipocyte differentiation and function. Cell culture studies using adipocytes have shown that NNMT overexpression promotes lipid accumulation and insulin resistance, while NNMT knockdown or inhibition increases NAD+ levels, activates SIRT1, enhances mitochondrial respiration, promotes expression of thermogenic genes including UCP1, and drives white adipocyte browning toward a beige phenotype.

5-Amino-1MQ Animal Studies

Studies using 5-Amino-1MQ specifically have demonstrated its potency and selectivity as an NNMT inhibitor, with IC50 values in the low micromolar range and good selectivity over other methyltransferases. Animal studies administering 5-Amino-1MQ orally to diet-induced mice have shown dose-dependent reductions in weight (typically 10-30% reduction compared to vehicle-treated controls over 4-12 week periods), with the weight primarily reflecting mass reduction while lean mass is preserved or even increased. Importantly, these effects occur without changes in food intake, indicating metabolic rather than anorectic mechanisms.

Treated animals show increased oxygen consumption and energy expenditure measured by indirect calorimetry, confirming enhanced metabolic rate. Histological analysis of adipose tissue from 5-Amino-1MQ-treated animals reveals increased presence of multilocular brown-like adipocytes, increased mitochondrial density, elevated expression of UCP1 and other thermogenic markers, and reduced adipocyte size. Glucose metabolism studies show improvements in glucose tolerance, insulin sensitivity, and reduced fasting glucose and insulin levels. Liver analyses demonstrate reduced hepatic triglyceride content (improvement in fatty liver).

5-Amino-1MQ is in early research stages with limited safety data. Preclinical studies suggest good tolerability, but comprehensive  trials are needed to establish safety profiles. As with any metabolic modulator, appropriate monitoring and research protocols are essential.